Profile: Santarus Inc (SNTS.O)
6 Dec 2013
Santarus, Inc. (Santarus), incorporated on April 22, 2002, is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company’s marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company’s investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody).
Marketed and Approved Products
Uceris (budesonide) extended release tablets is available in 9 mg tablets. It is a locally acting corticosteroid in an oral tablet formulation that utilizes multi-matrix system. Uceris is for the induction of remission in patients with active, mild to moderate ulcerative colitis. Zegerid (omeprazole/sodium bicarbonate) capsules and powder for oral suspension is available in 20 mg and 40 mg dosage strengths and is a immediate-release formulation of the proton pump inhibitor. Zegerid is for short-term treatment of active duodenal ulcer, short-term treatment of active benign gastric ulcer, treatment of gastroesophageal reflux disease, maintenance of healing of erosive esophagitis and reduction of risk of upper gastrointestinal, bleeding in critically ill patients. Glumetza is available in 500 milligram and 1000 milligram tablets and is a once-daily, extended-release formulation of metformin that incorporates drug delivery technology. Glumetza is an an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. Cycloset is available in 0.8 milligram tablets and is a formulation of bromocriptine, a dopamine receptor agonist that acts on the central nervous system. Cycloset is as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. Fenoglide is available in 40 milligram and 120 milligram tablets and is a formulation of fenofibrate that incorporates drug delivery technology. Fenoglide also is indicated as an adjunct to diet for treatment of adult patients with hypertriglyceridemia.
Ruconest (recombinant human C1 esterase inhibitor) is a recombinant version of the human protein C1 esterase inhibitor, which is produced using transgenic technology. In November 2012, the Company its results from the phase III clinical study of Ruconest for the treatment of acute attacks of angioedema in patients with hereditary angioedema. Rifamycin SV MMX is a spectrum, non-systemic antibiotic in an oral tablet formulation, which utilizes MMX colonic delivery technology and is being developed for the treatment of patients with travelers’ diarrhea. SAN-300 (anti-VLA-1 antibody) is an anti-VLA-1 monoclonal antibody drug developed for the treatment of rheumatoid arthritis.
Suite 400, 3611 Valley Centre Dr
SAN DIEGO CA 92130-3331
Company Web Links
- Salix sets launch of $1.35 billion loan for Santarus buy
- RLPC: Salix sets launch of $1.35B loan for Santarus buy
- US STOCKS-Wall St rebounds from selloff on strong payrolls data
- US STOCKS-Wall St jumps as strong payrolls ease Fed concern
- US STOCKS-Wall St rises after strong payrolls data eases Fed concern